Multiple Myeloma Clinical Trial

Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey

Summary

This study will evaluate the validity of using a survey to quantify patient preferences at the point-of-care and the potential effectiveness of the survey to improve goal-concordant care. The primary hypothesis is that by identifying the strength of patient preferences for outcomes with this survey clinicians will be able to improve goal-concordant care by aligning clinical recommendations with patients' preferences. This study will have 50 patients with newly diagnosed hematologic malignancy complete the survey throughout their disease course (up to 2 years) and conduct qualitative interviews with a subset (n = 20) of participants. The information obtained from these participants will be used to refine the survey. Interviews with oncologists and palliative care specialists (up to 10) will inform implementation.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Confirmed new diagnosis of one of the following hematologic malignancies: aggressive lymphoma, multiple myeloma, CLL, CML, AML, ALL, MDS EB1 or EB2
Age≥60
Ability to read, understand, and communicate fluently in English
Ability to understand and comply with study procedures
Willingness and ability to provide written informed consent

Exclusion Criteria:

Dementia, altered mental status, or psychiatric condition that would prohibit the understanding or rendering of informed consent or participation in the discrete choice experiment.
Significant medical conditions, as assessed by the investigators, that would substantially increase the burden on the patient to complete study assessments (such as multiorgan failure, respiratory failure, or other critical illness).

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

51

Study ID:

NCT05061095

Recruitment Status:

Completed

Sponsor:

UNC Lineberger Comprehensive Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Lineberger Comprehensive Cancer Center
Chapel Hill North Carolina, 27514, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

51

Study ID:

NCT05061095

Recruitment Status:

Completed

Sponsor:


UNC Lineberger Comprehensive Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.